InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: None

Saturday, 11/21/2020 2:55:22 PM

Saturday, November 21, 2020 2:55:22 PM

Post# of 6725
Arbutus is the best Long-term Biotech to own. Why?

1.) Because has chance to dose AB-729 once every 8 or once every 12 weeks. Future combinations could prove to be cures. Either all oral combo or AB-729 with other drugs

2.) ABUS collects payments from Alnylam for onpattro and has several other licensees for technology. Also may end up getting royalties through genevant for Pfizer/Biontech vaccine sales and Moderna Vaccine sales

3.) Pan coronavirus antiviral drug being developed. With Sofia having knowledge in antivirals company is working on a potential antiviral drug that could not only target the current coronavirus but any other type that mutates in the future. I consider this a long-term play on spike coronaviruses or any other viruses that may arise/mutate.

4.) PD-L1 1st generation. If you look at the pipeline the goal is to develop the company's own PD-L1 drug. Well it will be attempted with the Hepatitis B combination, but it could also become a multi-billion dollar drug targeting cancer like Keytruda, Opdivo, Avelumab, Tecentriq etc.

Based on everything this company currently shows in Hepatitis B with AB-729 and so much potential I believe it is a future buyout candidate at around $20 per share or higher. It's just that investors have to be patient with this one to achieve that goal. Even if it takes 2 years, which nobody knows, I feel ABUS will eventually be bought out.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABUS News